Blue Apron Holdings (NYSE: APRN) is scheduled to report its second quarter 2019 earnings results on Tuesday, August 6, before market open. Analysts expect the company to report a loss of $1.08 per share on revenue of $138 million.
There appears to be very little optimism surrounding Blue Apron in general. The company’s business model is both expensive and inefficient and it does not offer much incentive in terms of attracting new customers or retaining existing ones.
Blue Apron also faces tough competition from other delivery services as well as retailers like Walmart (NYSE: WMT) and Kroger (NYSE: KR) who offer lower-priced meal kits in their stores. This significantly hurts the company’s business.
In June, Blue Apron announced a 1-for-15 reverse stock split which helped it avoid delisting from the NYSE. Last month, the company announced it would start offering plant-based products from Beyond Meat (NASDAQ: BYND) on its menus from August.
Wall Street remains unimpressed with these two moves. Analysts do not see much benefit coming out of these actions and even though Blue Apron’s shares had spiked 20% on the Beyond Meat-alliance news, it was considered nothing more than a halo effect.
Analysts do not believe the partnership with Beyond Meat can save Blue Apron and the sentiment surrounding Blue Apron’s future prospects is bleak. Blue Apron would require a change in strategy fast in order to survive in this difficult environment.
In the first quarter of 2019, Blue Apron missed top line estimates while the bottom line was narrower-than-expected. Revenue fell 28% year-over-year to $141.9 million while net loss narrowed to $0.03 per share from $0.17 per share last year. Orders fell 29% while the number of customers dropped 30% from a year ago.
Blue Apron’s shares have dropped 52% year-to-date and 48% over the past three months. The stock has an average 12-month price target of $6.00.
The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for
The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated